<DOC>
	<DOCNO>NCT02914613</DOCNO>
	<brief_summary>The primary purpose study evaluate safety exploratory efficacy SF0166 Topical Ophthalmic Solution patient Diabetic Macular Edema ( DME ) .</brief_summary>
	<brief_title>Safety Exploratory Efficacy Study SF0166 Treatment Diabetic Macular Edema ( DME )</brief_title>
	<detailed_description>This prospective , randomize , double-masked , multicenter , Phase I/II clinical study 40 eligible subject active Diabetic Macular Edema ( DME ) randomize 1 2 treatment arm 1:1 ratio follow : SF0166 low dose twice daily ( BID ) SF0166 high dose BID . The study population include male female subject , age 18 old , diabetic macular edema ( i.e. , retinal thickening secondary type 1 type 2 diabetes mellitus Diabetic Macular Edema ( DME ) central subfield thickness ≥325 micron ( μm ) spectral domain optical coherence tomography [ OCT ] ) treatment antivascular endothelial growth factor ( VEGF ) therapy study eye within 60 day study entry . If subject qualifies eye , SF0166 may administer eye ( study eye non-study eye ) discretion Investigator . Study subject administer randomly assign treatment 28 day . There additional 28-day post-treatment follow-up period . All study subject return examination every 2 week 8 week ( 2 month ) . All outcomes assessment summarize descriptively Days 0 , 14 , 28 , 42 , 56 . No formal hypothesis test .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Male female , 18 year age old . 2 . Retinal thicken secondary type 1 type 2 diabetes mellitus Diabetic Macular Edema ( DME ) define central subfield thickness ≥325 micron ( µm ) spectral domain OCT study eye . 3 . Bestcorrected Visual Acuity ( BCVA ) 78 25 letter , inclusive , study eye screening/randomization visit use Early Treatment Diabetic Retinopathy Study ( ETDRS ) testing , BCVA decrement primarily attributable Diabetic Macular Edema ( DME ) . 4 . Treatment naïve ( i.e. , previous antivascular endothelial growth factor [ VEGF ] treatment study eye ) previously treat study eye adequate washout define : 1 . Lucentis ( ranibizumab ) : 30day washout 2 . Avastin ( bevacizumab ) : 30day washout 3 . Eylea ( aflibercept ) : 60day washout 4 . Macugen ( pegaptanib ) : 45day washout 5 . Willing able return study visit . 6 . Able adhere study dose requirement . 7 . Understands sign write informed consent form . 1 . Active proliferative diabetic retinopathy ( PDR ) study eye , neovascularization optic disc ( NVD ) , neovascularization elsewhere ( NVE ) , vitreous hemorrhage , neovascular glaucoma . 2 . Uncontrolled glaucoma ocular hypertension study eye define intraocular pressure ( IOP ) &gt; 25 millimeter mercury ( mmHg ) regardless concomitant treatment IOPlowering medication . 3 . Uncontrolled hypertension define systolic &gt; 180 mmHg &gt; 160 mmHg 2 consecutive measurement ( visit ) diastolic &gt; 100 mmHg optimal medical regimen . 4 . Screening glycated hemoglobin ( HbA1c ) blood test &gt; 12.0 % . 5 . Previous panretinal photocoagulation ( PRP ) study eye within 4 month study enrollment , need PRP study base Investigator 's opinion . 6 . Previous focal laser photocoagulation study eye , within foveal avascular zone . 7 . Intravitreal/periocular/topical ocular steroid type study eye within 90 day ( 3 month ) prior study enrollment . 8 . Placement Iluvien Retisert ( fluocinolone acetonide intravitreal implant ) study eye within 36 month ( 3 year ) prior study enrollment . 9 . Use Ozurdex ( dexamethasone intravitreal implant ) study eye within 180 day ( 6 month ) prior study enrollment . 10 . Significant epiretinal membrane , posterior hyaloidal traction , and/or vitreomacular traction study eye determine optical coherence tomography ( OCT ) result . 11 . Previous par plana vitrectomy study eye . 12 . Any intraocular surgery study eye within 90 day ( 3 month ) prior study enrollment . 13 . Yttrium aluminium garnet ( YAG ) laser treatment study eye within 30 day ( 1 month ) prior study enrollment . 14 . Concomitant use topical ophthalmic medication study eye , include dry eye glaucoma medication , unless stable dose least 90 day ( 3 month ) prior study enrollment expect stay stable dose throughout study participation . Artificial tear allow . 15 . High myopia study eye , spherical equivalent &gt; 8.00 Diopters ( D ) screening . 16 . Chronic recurrent uveitis study eye . 17 . Ongoing ocular infection inflammation either eye . 18 . A history cataract surgery complicate vitreous loss study eye . 19 . Congenital eye malformation study eye . 20 . A history penetrate ocular trauma study eye . 21 . Mentally handicap . 22 . Females childbearing potential ( i.e. , postmenopausal least 1 year surgically sterile least 6 week prior Visit 1 Screening/Randomization ) lactating , pregnant determine positive urine pregnancy test ( UPT ) Visit 1 Screening/Randomization . Women childbearing potential must agree use acceptable method birth control throughout study . Acceptable method birth control include tubal ligation , transdermal patch , intrauterine devices/systems , oral/implantable/injectable contraceptive , sexual abstinence , double barrier method , vasectomized partner . 23 . Participation investigational device drug clinical research study within 30 day Visit 1 Screening/Randomization . 24 . Contraindication study medication fluorescein dye . 25 . Other ocular pathology Investigator 's opinion would interfere subject 's vision study eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>